Funding of £5m will create new jobs in Norfolk
Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK
The new development will be based at Norwich Science Park and provide facilities for start-up and expanding businesses.
BBSRC will provide £500,000 as well as the land and buildings to host the new facilities, with £1.4m coming from the East of England Development Agency (EEDA), £1m from the Greater Norwich Development Partnership (GNDP), £500,000 from NRP partner the University of East Anglia (UEA), and the remainder from other NRP partners.
The new facilities, to be opened in July, will be managed by a new joint venture company called Colney Innovations (CIL).
David Parfrey, BBSRC director of finance and director of CIL, said: "The research carried out by the 2,000 scientists already working at Norwich Science Park is world-class and it makes absolute sense to create a facility on this site where the results of such research can be taken through to applications."
Prof Douglas Kell, chief executive of BBSRC, added: "The Norwich Research Park is home to three world-class BBSRC institutes: the John Innes Centre, the Institute of Food Research and The Genome Analysis Centre. This new facility will play a key role in helping our scientists, and others, to translate their excellent science into products to benefit the economy and people of the UK."
You may also like
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
Read moreNew draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Trending Articles
You may also like
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster